Topol E - Search Results

1

The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention.

Kelly RV, Hsu A, Topol E, Steinhubl S. Kelly RV, et al. Among authors: topol e. J Invasive Cardiol. 2006 Mar;18(3):115-9. J Invasive Cardiol. 2006. PMID: 16598110 Clinical Trial.

2

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Steinhubl SR, et al. JAMA. 2002 Nov 20;288(19):2411-20. doi: 10.1001/jama.288.19.2411. JAMA. 2002. PMID: 12435254 Clinical Trial.

3

Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.

Brener SJ, Steinhubl SR, Berger PB, Brennan DM, Topol EJ; CREDO Investigators. Brener SJ, et al. J Invasive Cardiol. 2007 Jul;19(7):287-90. J Invasive Cardiol. 2007. PMID: 17620671 Clinical Trial.

4

Timing and correlates of very early major adverse clinical events following percutaneous coronary intervention.

Jozic J, Orford J, Steinhubl S, Berger P, Hsu A, Topol E. Jozic J, et al. Among authors: topol e. J Invasive Cardiol. 2008 Mar;20(3):113-8. J Invasive Cardiol. 2008. PMID: 18316826

5

Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization.

Chiu JH, Topol EJ, Whitlow PL, Hsu AP, Tuzcu EM, Franco I, Moliterno DJ. Chiu JH, et al. Among authors: topol ej. Am J Cardiol. 2003 Sep 1;92(5):582-3. doi: 10.1016/s0002-9149(03)00726-4. Am J Cardiol. 2003. PMID: 12943879

6

Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old.

Mukherjee D, Hsu A, Moliterno DJ, Lincoff AM, Goormastic M, Topol EJ. Mukherjee D, et al. Am J Cardiol. 2003 Dec 15;92(12):1465-7. doi: 10.1016/j.amjcard.2003.08.062. Am J Cardiol. 2003. PMID: 14675589

7

Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.

Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Brener SJ, et al. Among authors: topol ej. Circulation. 2004 Aug 24;110(8):994-8. doi: 10.1161/01.CIR.0000139868.53594.24. Epub 2004 Aug 9. Circulation. 2004. PMID: 15302778

8

Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention.

Saw J, Topol EJ, Steinhubl SR, Brennan D, Berger PB, Moliterno DJ; CREDO Investigators. Saw J, et al. Am J Cardiol. 2004 Sep 1;94(5):623-5. doi: 10.1016/j.amjcard.2004.05.026. Am J Cardiol. 2004. PMID: 15342293

9

Risk reduction with long-term clopidogrel following percutaneous coronary intervention.

Steinhubl SR, Topol EJ. Steinhubl SR, et al. Eur Heart J. 2004 Dec;25(23):2169-70; author reply 2170-1. doi: 10.1016/j.ehj.2004.08.011. Eur Heart J. 2004. PMID: 15571836 No abstract available.

10

Variability in platelet responsiveness to clopidogrel among 544 individuals.

Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Serebruany VL, et al. J Am Coll Cardiol. 2005 Jan 18;45(2):246-51. doi: 10.1016/j.jacc.2004.09.067. J Am Coll Cardiol. 2005. PMID: 15653023 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,305 results

Search Page

Filters